Mettine H A Bos

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 7

Top Topics

Trauma Patients

Venous Thromboembolism

Top Venues

Pharmacotherapy

Research and practice in thrombosis and haemostasis

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Mettine H A Bos, Rianne Elaine van Diest, Dougald M Monroe
Blood coagulation factor IX: structural insights impacting hemophilia B therapy. Blood (2024)
Eleonora Camilleri, Mira Ghobreyal, Mettine H A Bos, Pieter H Reitsma, Felix J M Van Der Meer, Jesse Joachim Swen, Suzanne C Cannegieter, Nienke van Rein
Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort. Pharmacotherapy (2024)
Eleonora Camilleri, Mira Ghobreyal, Mettine H A Bos, Pieter H Reitsma, Felix J M Van Der Meer, Jesse Joachim Swen, Suzanne C Cannegieter, Nienke van Rein
Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort. Pharmacotherapy 44 (6) (2024)
Carolina E Touw, Banne Nemeth, Araci M R Rondon, Raymond A van Adrichem, J P Luyendyk, Henri H Versteeg, Inger Birgitta Schipper, Rob G H H Nelissen, Mettine H A Bos, Suzanne C Cannegieter
Lower-leg injury and knee arthroscopy have distinct effects on coagulation. Blood advances 6 (17) (2022)
Bianca Op den Brouw, Parviz Ghezellou, Nicholas R Casewell, Syed Abid Ali, Behzad Fathinia, Bryan Grieg Fry, Mettine H A Bos, Maria P Ikonomopoulou
Pharmacological Characterisation of Pseudocerastes and Eristicophis Viper Venoms Reveal Anticancer (Melanoma) Properties and a Potentially Novel Mode of Fibrinogenolysis. International journal of molecular sciences 22 (13) (2021)
Mettine H A Bos, Henri H Versteeg
Snakebites and microvesicles: Popping bubbles. Research and practice in thrombosis and haemostasis 3 (2) (2019)
Daniël Verhoef, Koen M Visscher, C Ruben Vosmeer, Ka Lei Cheung, Pieter H Reitsma, Daan P Geerke, Mettine H A Bos
Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors. Nature communications 8 (1) (2017)